You are now leaving GSK’s website

This link will take you to a non-GSK website. GSK does not recommend, endorse or accept liability for sites controlled by third-parties.


Go back

Introducing Trelegy Ellipta

The only COPD Triple Therapy delivered in a single daily inhalation 1

TRELEGY Ellipta OD is indicated for maintenance treatment in adult patients with moderate to severe COPD who are not adequately treated by a combination of an ICS and a LABA, or a combination of a LABA and a LAMA 1

Request an Ellipta demonstration device

Simplicity is key

Would your COPD patients prefer a simple dosing routine? A single daily inhalation from the easy-to-use Ellipta inhaler  [3-5]

Learn more


FEV1, forced expiratory volume in one second; FF, fluticasone furoate; ICS, inhaled corticosteroid; LABA, long-acting ß2-agonist; LAMA, long-acting muscarinic antagonist; OD, once-daily; UMEC, umeclidinium; VI, vilanterol


  1. TRELEGY Ellipta SmPC, 2018. Available at [Last accessed December 2018]
  2. Lipson DA et al. N Engl J Med 2018; 378:1671–1680.
  3. van der Palen J et al. NPJ Prim Care Respir Med 2016; 26:16079.
  4. Svedsater H et al. BMC Pulm Med 2013; 13:72–86.
  5. Riley J et al. Int J Chron Obstruct Pulmon Dis 2016; 11:1873–1880.
  6. Lipson DA et al. Am J Respir Crit Care Med 2017; 196:438–446.
  7. Cazzola M et al. Pulm Pharmacol Ther 2010; 23:257–267.

TRELEGY Ellipta was developed in collaboration with INNOVIVA Inc.

Adverse events should be reported to the Health Products Regulatory Authority (HPRA) using an Adverse Reaction Report Form obtained either from the HPRA or electronically via the website at Adverse reactions can also be reported to the HPRA by calling: (01) 6764971. Adverse events should also be reported to GlaxoSmithKline on 1800 244 255.

▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.